|
|
||||||||
Ann Thorac Surg 2005;80:757-767
© 2005 The Society of Thoracic Surgeons
a Department of Surgery, Oregon Health & Science University, Portland, Oregon
b Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China
c Providence Heart Institute, Albert Starr Academic Center, Portland, Oregon
d Wuhan Heart Institute, The Central Hospital of Wuhan, Wuhan, China
* Address reprint requests to Prof He, Department of Surgery, The Chinese University of Hong Kong, Block B, 5A, Prince of Wales Hospital, Shatin, N.T., Hong Kong SAR, China (Email: gwhe{at}cuhk.edu.hk).
Cardioplegic (and organ preservation) solutions were initially designed to protect the myocardium (cardiac myocytes) during cardiac operation (and heart transplantation). Because of differences between cardiac myocytes and vascular (endothelial and smooth muscle) cells in structure and function, the solutions may have an adverse effect on coronary vascular cells. However, such effect is often complicated by many other factors such as ischemia-reperfusion injury, temperature, and perfusion pressure or duration. To evaluate the effect of a solution on the coronary endothelial function, a number of points should be taken into consideration. First, the overall effect on endothelium should be identified. Second, the effect of the solution on the individual endothelium-derived relaxing factors (nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor) must be distinguished. Third, the effect of each major component of the solution should be investigated. Lastly, the effect of a variety of new additives in the solution may be studied. Based on available literature these issues are reviewed to provide information for further development of cardioplegic or organ preservation solutions.
This article has been cited by other articles:
![]() |
M. Wu, Q. Yang, A. P.C. Yim, M. J. Underwood, and G.-W. He Cellular electrophysiologic and mechanical evidence of superior vascular protection in pulmonary microcirculation by Perfadex compared with Celsior. J. Thorac. Cardiovasc. Surg., February 1, 2009; 137(2): 492 - 498. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |